NCT06883240

An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment

A Multicenter Non-Interventional Study Evaluating Bleeds and Health-Related Quality Of Life in Patients With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 40 (estimated)
• Sponsor: Hoffmann-La Roche · Industry
• Sex: All
• Age: 2 Years
• Healthy volunteers: Not accepted

Summary

This non-interventional study (NIS) is designed to collect information on the effectiveness and safety of treatment received in routine clinical care, as well as measure the health-related quality of life (HRQoL) of participants with Type 3 von Willebrand disease (VWD) receiving prophylactic therapy per local standard of care (SOC) over an observation period of at least 24 weeks.

Conditions

• Von Willebrand Disease, Type 3

Interventions

Type	Name	Description
DRUG	Von Willebrand Factor Concentrates	Used according to local labeling or local treatment guidelines.
DRUG	Von Willebrand Factor Concentrates and Factor VIII Concentrates	Used according to local labeling or local treatment guidelines.
DRUG	Factor VIII Concentrates	Used according to local labeling or local treatment guidelines.
DRUG	Recombinant Activated Factor VII	Used according to local labeling or local treatment guidelines.
DRUG	Activated Prothrombin Complex Concentrate	Used according to local labeling or local treatment guidelines.

Timeline

• Start date: 2025-04-29
• Primary completion: 2026-11-01
• Completion: 2026-11-01
• First posted: 2025-03-19
• Last updated: 2026-04-17

Locations

27 sites across 14 countries: United States, Belgium, Canada, Colombia, France, Germany, Italy, Japan, Netherlands, Poland, South Africa, Spain, Sweden, United Kingdom

Regulatory

• FDA-regulated drug study